Systematic Financial Management LP Invests $9.15 Million in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Systematic Financial Management LP bought a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 246,348 shares of the company's stock, valued at approximately $9,147,000. Systematic Financial Management LP owned 0.51% of Amphastar Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Smartleaf Asset Management LLC increased its stake in Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after purchasing an additional 493 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Amphastar Pharmaceuticals by 806.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock valued at $36,000 after purchasing an additional 871 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Amphastar Pharmaceuticals by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after buying an additional 348 shares in the last quarter. Huntington National Bank raised its holdings in shares of Amphastar Pharmaceuticals by 36.9% during the fourth quarter. Huntington National Bank now owns 1,340 shares of the company's stock valued at $50,000 after acquiring an additional 361 shares during the last quarter. Finally, TD Private Client Wealth LLC lifted its position in shares of Amphastar Pharmaceuticals by 22.7% in the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock valued at $78,000 after acquiring an additional 388 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the company's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the transaction, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. This represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 5,231 shares of company stock worth $142,752 in the last 90 days. 27.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on AMPH. Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research report on Friday, March 21st. Wells Fargo & Company dropped their target price on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $30.00 price target (down from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $32.33.

Amphastar Pharmaceuticals Stock Down 3.6%

Amphastar Pharmaceuticals stock traded down $0.91 during mid-day trading on Wednesday, hitting $24.16. The company had a trading volume of 341,425 shares, compared to its average volume of 478,700. The business has a fifty day moving average of $25.33 and a 200 day moving average of $33.42. Amphastar Pharmaceuticals, Inc. has a 1 year low of $22.64 and a 1 year high of $53.96. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of 8.05, a PEG ratio of 2.19 and a beta of 0.78.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.